Evidence map›Paper›PMID 34489712›Full record

ArticleFrontiers in pharmacology2021

Safety, Tolerability and Pharmacokinetics of the Serotonin 5-HT6 Receptor Antagonist, HEC30654, in Healthy Chinese Subjects.

Xiaojiao Li, Lei Gao, Jingrui Liu, Hong Zhang, Hong Chen, Lizi Yang, Min Wu, Cuiyun Li, Xiaoxue Zhu, Yanhua Ding and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Serotonin 5-HTInternational journal of molecular sciences · 2022
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xiaojiao LiPhase I Clinical Trial Unit, The First Hospital of Jilin University, Changchun, China.
Lei GaoPhase I Clinical Trial Unit, The First Hospital of Jilin University, Changchun, China.
Jingrui LiuPhase I Clinical Trial Unit, The First Hospital of Jilin University, Changchun, China.
Hong ZhangPhase I Clinical Trial Unit, The First Hospital of Jilin University, Changchun, China.
Hong ChenPhase I Clinical Trial Unit, The First Hospital of Jilin University, Changchun, China.
Lizi YangNanguan District Maternal and Child Health and Family Planning Service Center of Changchun, Changchun, China.
Min WuPhase I Clinical Trial Unit, The First Hospital of Jilin University, Changchun, China.
Cuiyun LiPhase I Clinical Trial Unit, The First Hospital of Jilin University, Changchun, China.
Xiaoxue ZhuPhase I Clinical Trial Unit, The First Hospital of Jilin University, Changchun, China.
Yanhua DingPhase I Clinical Trial Unit, The First Hospital of Jilin University, Changchun, China.
Li SunDepartment of Neurology and Neuroscience Center, The First Hospital of Jilin University, Changchun, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

5-HT6 receptor antagonistHEC30654pharmacokineticsphase Isafety

Identifiers

PMID34489712
PMCPMC8416768

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.